drugset / Trial / NCT02256722

In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects

NCT02256722

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to compare the metabolic and electrolyte effects of a single oral dose of 320 mg ritobegron administered alone or with a pre- and comedication with bisoprolol, propranolol and acipimox. In addition, to compare the metabolic and electrolyte effects of a single dose of 320 mg ritobegron with those of a single inhalatory dose of 100 μg salmeterol

Timeline

Start
2005-10
Primary completion
2005-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Acipimox Small molecule 500 mg
Subject Bisoprolol Other / unclassified 10 mg
Subject Propranolol Small molecule 160 mg
Subject Ritobegron Small molecule 320 mg Oral
Comparator Salmeterol Other / unclassified 100 ug Inhaled

Indications

No indication recorded.